CDTX
Price
$24.05
Change
-$0.00 (-0.00%)
Updated
Jun 5 closing price
Capitalization
311.92M
PRME
Price
$1.64
Change
+$0.28 (+20.59%)
Updated
Jun 6, 11:06 AM (EDT)
Capitalization
179.87M
61 days until earnings call
Interact to see
Advertisement

CDTX vs PRME

Header iconCDTX vs PRME Comparison
Open Charts CDTX vs PRMEBanner chart's image
Cidara Therapeutics
Price$24.05
Change-$0.00 (-0.00%)
Volume$225.73K
Capitalization311.92M
Prime Medicine
Price$1.64
Change+$0.28 (+20.59%)
Volume$17.71K
Capitalization179.87M
CDTX vs PRME Comparison Chart
Loading...
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDTX vs. PRME commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDTX is a Hold and PRME is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (CDTX: $24.05 vs. PRME: $1.37)
Brand notoriety: CDTX and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDTX: 136% vs. PRME: 167%
Market capitalization -- CDTX: $311.92M vs. PRME: $179.87M
CDTX [@Biotechnology] is valued at $311.92M. PRME’s [@Biotechnology] market capitalization is $179.87M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDTX’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • CDTX’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, both CDTX and PRME are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDTX’s TA Score shows that 5 TA indicator(s) are bullish while PRME’s TA Score has 3 bullish TA indicator(s).

  • CDTX’s TA Score: 5 bullish, 5 bearish.
  • PRME’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, both CDTX and PRME are a good buy in the short-term.

Price Growth

CDTX (@Biotechnology) experienced а +9.22% price change this week, while PRME (@Biotechnology) price change was +8.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

CDTX is expected to report earnings on May 08, 2025.

PRME is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDTX($312M) has a higher market cap than PRME($180M). CDTX YTD gains are higher at: -10.528 vs. PRME (-53.082). CDTX (-192.6M) and PRME (-200M) have comparable annual earnings (EBITDA) . CDTX has more cash in the bank: 168M vs. PRME (144M). CDTX has less debt than PRME: CDTX (2.67M) vs PRME (121M). PRME has higher revenues than CDTX: PRME (3.85M) vs CDTX (302K).
CDTXPRMECDTX / PRME
Capitalization312M180M173%
EBITDA-192.6M-200M96%
Gain YTD-10.528-53.08220%
P/E RatioN/AN/A-
Revenue302K3.85M8%
Total Cash168M144M117%
Total Debt2.67M121M2%
FUNDAMENTALS RATINGS
CDTX vs PRME: Fundamental Ratings
CDTX
PRME
OUTLOOK RATING
1..100
803
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
37
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
4194
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (37) in the null industry is somewhat better than the same rating for CDTX (77) in the Biotechnology industry. This means that PRME’s stock grew somewhat faster than CDTX’s over the last 12 months.

PRME's Profit vs Risk Rating (100) in the null industry is in the same range as CDTX (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to CDTX’s over the last 12 months.

PRME's SMR Rating (96) in the null industry is in the same range as CDTX (98) in the Biotechnology industry. This means that PRME’s stock grew similarly to CDTX’s over the last 12 months.

CDTX's Price Growth Rating (41) in the Biotechnology industry is somewhat better than the same rating for PRME (94) in the null industry. This means that CDTX’s stock grew somewhat faster than PRME’s over the last 12 months.

CDTX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that CDTX’s stock grew similarly to PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDTXPRME
RSI
ODDS (%)
Bearish Trend 1 day ago
87%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 4 days ago
77%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
Bearish Trend 8 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
87%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
THOCX39.670.21
+0.53%
Thornburg Global Opportunities C
ASQIX15.57N/A
N/A
American Century Small Company Inv
OLVRX20.13N/A
N/A
JPMorgan Large Cap Value R4
VDMCX9.92N/A
N/A
Virtus KAR Developing Markets C
QLSGX27.35N/A
N/A
Federated Hermes MDT Small Cap Growth R6

CDTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDTX has been closely correlated with BPTSY. These tickers have moved in lockstep 92% of the time. This A.I.-generated data suggests there is a high statistical probability that if CDTX jumps, then BPTSY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDTX
1D Price
Change %
CDTX100%
N/A
BPTSY - CDTX
92%
Closely correlated
N/A
REPL - CDTX
39%
Loosely correlated
+0.62%
IVVD - CDTX
36%
Loosely correlated
-4.55%
CVAC - CDTX
36%
Loosely correlated
+0.56%
PRME - CDTX
35%
Loosely correlated
+3.79%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+3.79%
CRSP - PRME
63%
Loosely correlated
+1.37%
RXRX - PRME
56%
Loosely correlated
-7.13%
BEAM - PRME
56%
Loosely correlated
-0.87%
ABCL - PRME
51%
Loosely correlated
-2.27%
CCCC - PRME
50%
Loosely correlated
-4.87%
More